This HTML5 document contains 153 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q35943499
rdf:type
wikibase:Item
schema:description
научни чланак vědecký článek 2016年论文 artikull shkencor articolo scientifico 2016年论文 naučni članak bilimsel makale научная статья 2016年の論文 գիտական հոդված artigo científico 2016 nî lūn-bûn vitenskapelig artikkel artykuł naukowy 2016年論文 мақолаи илмӣ article scientifique (publié 2016) tieteellinen artikkeli teaduslik artikkel artigo científico (publicado na 2016) scientific article научни чланак наукова стаття, опублікована в лютому 2016 2016년 논문 videnskabelig artikel (udgivet 2016) 2016年论文 سائنسی مضمون artículo científico publicado en 2016 article scientific научна статия مقالهٔ علمی vetenskaplig artikel 2016年論文 articol științific επιστημονικό άρθρο tudományos cikk บทความทางวิทยาศาสตร์ article científic 2016年论文 scienca artikolo bài báo khoa học mokslinis straipsnis artículu científicu espublizáu en 2016 ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artikulong pang-agham мақолаи илмӣ 2016年论文 מאמר מדעי artigo científico (publicado na 2016) مقالة علمية wissenschaftlicher Artikel 2016年論文 wetenschappelijk artikel vedecký článok 2016年論文 vitskapeleg artikkel სამეცნიერო სტატია 2016年論文 2016年论文
p:P577
wds:Q35943499-7A25313B-69C2-45C2-BB48-4CA1CE5D4799
wdt:P577
2016-02-25T00:00:00Z
p:P407
wds:Q35943499-0694262f-459c-ead1-de77-064483f0a23c
wdt:P407
wd:Q1860
p:P2860
wds:Q35943499-1B40386A-43CF-489B-921B-C36E4A720FAB wds:Q35943499-6DBFA499-BEE8-45B5-9A0E-EA5773ADD547 wds:Q35943499-6DC18E34-5AEE-4584-995B-5B478E844F54 wds:Q35943499-7E95DA90-4099-4619-B28E-BAB19E191D0A wds:Q35943499-8C60A684-70C3-42B4-9726-68386515079D wds:Q35943499-91DE681B-1EF8-497F-8410-3A3E47652E6A wds:Q35943499-3DE382A4-5B49-4AA5-95CB-BB483574C911 wds:Q35943499-4E23F5FA-B0F9-4520-A653-E0359AD8EA45 wds:Q35943499-5C0C90EF-4836-471D-AEB5-0D263CDD4943 wds:Q35943499-F2BB6A23-69AC-461A-B251-90B993F5E5FB wds:Q35943499-FC8EBFDB-B609-407C-803C-8900493D43E5 wds:Q35943499-115ED4A8-8741-40BB-95E2-0C1A49A068C3
wdt:P2860
wd:Q28294837 wd:Q44704962 wd:Q35704462 wd:Q29619529 wd:Q24633874 wd:Q38233507 wd:Q41494022 wd:Q35575496 wd:Q33646777 wd:Q33567438 wd:Q81908646 wd:Q34157994
p:P2093
wds:Q35943499-E65CC9C8-702F-44F7-8ED9-95E3D37B5EAA wds:Q35943499-E05D4C90-C5F6-4EDF-8406-861AB1B4B669 wds:Q35943499-8866BAA7-7C03-4B80-A92F-E88A9EF63DE9 wds:Q35943499-5C67FFB6-25A2-426A-9095-A08A2586B3D2 wds:Q35943499-5A3ACE3A-690B-4EE2-8702-E6AA7912DD9E wds:Q35943499-5BC7158B-83E1-4BBB-B7EA-AB687C0114C1 wds:Q35943499-43D2FB68-5751-4B75-8049-9220651D9C35
wdt:P2093
John A Wells Chirag Jhaveri Frederick L Ferris Allison R Ayala G Robert Hampton Michele Melia Alexander J Brucker
rdfs:label
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
skos:prefLabel
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
schema:name
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
p:P50
wds:Q35943499-A2918E03-0E3E-427A-AAE3-605EF9CF4549 wds:Q35943499-A978B414-7F04-4E94-99BD-7E32A8CA0168 wds:Q35943499-482E71B9-1070-4F9C-B990-029C454FC055 wds:Q35943499-80A222A0-C3A9-47CD-9BDD-6F0F70B3BEAB wds:Q35943499-3868E63C-3CDD-48EF-AE6C-8DCA4457E15A wds:Q35943499-161FCEA1-A0EA-47BC-A8E4-BEE2CACA1852
wdt:P50
wd:Q111076721 wd:Q88156417 wd:Q98806904 wd:Q98807054 wd:Q114739669 wd:Q112187433
p:P1476
wds:Q35943499-3BC1FD74-742C-41DE-8E6B-33E28E33C1DC
wdt:P1476
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
p:P304
wds:Q35943499-B17631F7-09BE-4453-B0EF-AA444D8F9589
wdt:P304
1351-1359
p:P31
wds:Q35943499-36D33861-DF77-430A-ADF1-B4ABDEB95025
wdt:P31
wd:Q13442814
p:P921
wds:Q35943499-2FCA117D-96E3-46C7-83BB-0EAEEABAE149 wds:Q35943499-DE1E86CC-6060-4AE8-979C-B6FE0BF21442 wds:Q35943499-AF90B074-5676-4611-9792-EA22DFE13BAF
wdt:P921
wd:Q4689286 wd:Q18558081 wd:Q413299
p:P698
wds:Q35943499-E0FA1088-4610-4AFA-9A4F-7C3E904EEE0F
wdtn:P698
n12:26935357
wdt:P698
26935357
p:P1433
wds:Q35943499-DBB0D3A6-EDB5-489E-A913-22AC6EF8A2FB
wdt:P1433
wd:Q7098109
p:P433
wds:Q35943499-3860CB93-B787-4FAC-B977-14968372494A
p:P478
wds:Q35943499-BE1D5F04-3E66-4522-8B0D-EB8E78D35E13
wdt:P433
6
wdt:P478
123
p:P356
wds:Q35943499-F22A27BA-30C2-4A77-9213-A74AFD413242
wdtn:P356
n11:J.OPHTHA.2016.02.022
wdt:P356
10.1016/J.OPHTHA.2016.02.022
p:P932
wds:Q35943499-B8360182-DB13-4C8E-A3EC-F3E838A380DA
wdt:P932
4877252